GlaxoSmithKline PLC Landmark IMPACT study to be published in NEJM (3186L)
18 April 2018 - 7:34PM
UK Regulatory
TIDMGSK
RNS Number : 3186L
GlaxoSmithKline PLC
18 April 2018
Issued: 18 April 2018, London UK - LSE Announcement
Landmark IMPACT study to be published in NEJM
GlaxoSmithKline plc (LSE/NYSE: GSK) will today announce at 22:00
BST its IMPACT data.
GSK - a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com.
GSK enquiries:
UK Media enquiries: Simon Steel +44 (0) 20 8047 (London)
5502
David Daley +44 (0) 20 8047 (London)
5502
Analyst/Investor Sarah Elton-Farr +44 (0) 20 8047 (London)
enquiries: 5194
Tom Curry + 1 215 751 5419 (Philadelphia)
James Dodwell +44 (0) 20 8047 (London)
2406
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item
3.D Principal risks and uncertainties in the company's Annual
Report on Form 20-F for 2017.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCKVLBFVZFXBBF
(END) Dow Jones Newswires
April 18, 2018 05:34 ET (09:34 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024